Elias Jabbour - How I treat the older adult with ALL

(14:30)

Meet leukemia oncologist Elias Jabbour, M.D.

(1:40)

The HemOnc Pulse Live at ASH 2022: Elias Jabbour, MD, on Immunotherapy Advances in ALL

(2:38)

2023 EHA Leukemia Update from Elias Jabbour, MD

(1:48)

Elias Jabbour - How I treat CML at MD ANDERSON CANCER CENTER in 2022

(16:32)

Elias Jabbour, MD, on the Phase III PhALLCON Trial in Ph+ ALL

(1:54)

Elias Jabbour, MD, talks about obe-cel ASH updates, FDA approval

(2:21)

Chronic Myeloid Leukemia (CML) Update - Interview with Elias Jabbour, M.D.

(4:22)

Elias Jabbour tells about 4th Soho Italy Annual Conference

(1:54)

Elias Jabbour, MD invites you to the 6th Annual Live Medical Crossfire®: Hematologic Malignancies

(52)

\

(4:25)

Elias Jabbour, MD shares hot topics at 6th Annual Live Medical Crossfire®: Hematologic Malignancies

(43)

Beyond HCVAD: Exploring Ways to Reduce Myelosuppression - Elias Jabbour, MD

(12:6)

King Hussein Award for Cancer Research 2022 - Professor Elias Jabbour

(1:12)

Elias Jabbour, MD | Reasons to Attend 2019 ASCO Direct Highlights Denver

(31)

Dr. Elias Jabbour: Long-Term Outcome with Hypomethylating Agents (HMA) for patients with MDS

(3:21)

Socialist Democracy Elias Jabbour

(10:57)

Dr. Jabbour on Emerging Subsets in ALL

(1:33)

HEM-ONC CHAT: Dr. Elias Jabbour, 'Treatment a la Carte in CML'

(4:23)

Elias Jabbour, MD | Key Takeaways in Leukemia Cancers at 2019 ASCO Direct Highlights Denver

(2:37)